化瘀镇痛方联合氯化锶治疗骨转移性癌痛临床研究

Clinical Study on Huayu Zhentong Prescription Combined with Strontium Chloride for Bone Metastasis with Cancer Pain

目的:观察化瘀镇痛方联合氯化锶治疗骨转移瘤患者癌性疼痛的临床疗效及安全性。方法:选取68例骨转移性癌痛患者,按随机数字表法分为观察组及对照组各34例。对照组在口服镇痛药物的基础上给予氯化锶治疗,观察组在对照组基础上加用化瘀镇痛方治疗,2组疗程均为14 d。比较2组治疗前后疼痛程度[疼痛数字评分法(NRS)评分]、生活质量[卡氏(KPS)评分]、疼痛标志物[内皮素-1 (ET-1)、肿瘤坏死因子-α(TNF-α)水平]变化,观察2组临床疗效及不良反应发生率。结果:治疗后,2组NRS评分均较治疗前降低,观察组NRS评分低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组KPS评分均较治疗前上升,观察组KPS评分高于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组临床疗效总有效率为88.24%,高于对照组73.53%,差异有统计学意义(P<0.05)。治疗后,2组ET-1、TNF-α水平均较治疗前降低,观察组上述2项水平均低于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率为20.59%,对照组不良反应发生率为17.65%,2组比较,差异无统计学意义(P>0.05)。结论:化瘀镇痛方联合氯化锶治疗骨转移性癌痛临床疗效较好,可缓解患者疼痛,改善生活质量,用药安全性较高。

Objective:To observe the clinical effect and safety of the therapy of Huayu Zhentong prescription combined with strontium chloride on cancer pain in patients with bone metastases. Methods:A total of 68 bone metastases patients with cancer pain were selected and divided into the observation group and the control group according to the random number table method,with 34 cases in each group. The control group was additionally treated with strontium chloride based on the treatment of oral administration of analgesic medicines, and the observation group was additionally treated with Huayu Zhentong prescription based on the treatment of the control group. Both groups were treated for 14 days. Before and after treatment,the degrees of pain in the two groups were compared by Numerical rating scale(NRS) score,quality of life by karnofsky(KPS) score,and pain markers by levels of endothelin-1(ET-1) and tumor necrosis factor-α(TNF-α). The clinical effects and incidences of adverse reactions were observed. Results:After treatment,the NRS scores in the two groups were decreased when compared with those before treatment,and the NRS score in the observation group was lower than that in the control group,the difference being significant(P<0.05). After treatment,the KPS scores in the two groups were increased when compared with those before treatment,and the KPS score in the observation group was higher than that in the control group,differences being significant(P<0.05). After treatment,the total clinical effective rate was 88.24% in the observation group, higher than that of 73.53% in the control group, the difference being significant(P<0.05). After treatment,the levels of ET-1 and TNF-α in both groups were decreased when compared with those before treatment,and the above two levels in the observation group were lower than those in the control group,differences being significant(P<0.05). The incidence of adverse reactions was 20.59% in the observation group, and 17.65% in the control group, there being no significance in the difference(P>0.05). Conclusion: The therapy of Huayu Zhentong prescription combined with strontium chloride for bone metastasis with cancer pain has a good clinical effect,which can relieve the pain of patients and improve the quality of life,with high administration safety.